Promising prostate cancer trial pulled before it began
NCT ID NCT07025512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test a radioactive drug (177Lu-PSMA-617) in men with advanced prostate cancer that has spread to the bone marrow and caused low blood cell counts. The goal was to see if the treatment was safe and how it affected the cancer. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can less be more? testing transfusion limits in ECMO
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- A simple blood test trend may flag ICU patients at risk
- Can an immune booster make hormone therapy work better against prostate cancer?